Polyrizon Ltd(PLRZ) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 4:00 PM ET (Korea 10/22 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.75 | Insider Own | 0.59% | Shs Outstand | 2.4M | Perf Week | -14.51% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.4M | Perf Month | -16.51% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 9.31% | Short Float | 2.15% | Perf Quarter | -41.87% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | -2.63% | Short Ratio | 0.83 | Perf Half Y | -39.21% |
| Sales | 0.00B | P/B | 0.77 | EPS next 5Y | - | ROA | -21.02% | Short Interest | 0.05M | Perf YTD | 4.83% |
| Book/sh | 11.49 | P/C | 1.4 | EPS past 3/5Y | 80.47% 39.74% | ROE | -21.42% | 52W High | -51.1% ($18.20) | Perf Year | 30.12% |
| Cash/sh | 6.35 | P/FCF | - | Sales past 3/5Y | - | ROIC | -18.77% | 52W Low | 209.03% ($2.88) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.2% | Gross Margin | - | Volatility(W/M) | 12.22% 9.67% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.97 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 36.37 | EPS Q/Q | -6.93% | Profit Margin | - | RSI (14) | 38.51 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 36.37 | Sales Q/Q | - | SMA20 | -9.06% ($9.79) | Beta | -1.12 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -17.15% ($10.74) | Rel Volume | 0.11 | Prev Close | $9.15 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -30.4% ($12.79) | Avg Volume(3M) | 0.06M | Price | $8.9 |
| IPO | 2024/10/29 | Option/Short | No/Yes | Trades | 189 | Volume | 6,963 | Change | -2.73% |
Polyrizon is a development-stage biotech company headquartered in Israel that develops nasal sprays using its proprietary Capture & Contain™ (C&C) hydrogel platform to form a physical protective barrier inside the nasal cavity. Its lead pipeline candidates include PL-14 (NASARIX™) for blocking pollens and allergens, PL-16 aimed at reducing exposure to respiratory viruses, and a nasal naloxone hydrogel, among others. The company is a nano-cap stock listed on Nasdaq.
Over the past 1 year, roughly in the middle
51% below its 1-year high.
Traded less than usual. That is 11% of its average volume.
PLRZ has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.3%.
Tap to view numbers
It ranks #463 of 595 in the industry
Based on market cap of $21M.
FAQ
What kind of company is PLRZ?
PLRZ belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PLRZ?
The market cap of PLRZ is approximately $21M, ranking 5,207 within its sector.
What is the 52-week high and low for PLRZ?
PLRZ has recorded a 52-week high of $18.20 and a low of $2.88.
